Morgan Stanley Maintains Equal-Weight on Sage Therapeutics, Maintains $49 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit maintains an Equal-Weight rating on Sage Therapeutics (NASDAQ:SAGE) and keeps the price target at $49.
August 04, 2023 | 1:47 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley maintains an Equal-Weight rating on Sage Therapeutics and keeps the price target at $49.
The news is directly about Sage Therapeutics. Morgan Stanley's decision to maintain an Equal-Weight rating and a $49 price target indicates a neutral outlook for the stock in the short term. This could potentially keep the stock's price stable.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100